Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q4 FY24 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, May 17, 2024
Slide 1: Covering letter to BSE and NSE
May 17, 2024 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please find
Slide 2: Earnings Presentation: Q4 and Full Year FY24
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation: Q4 and Full Year FY24 17th May, 2024 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q4 FY24: At a Glance
Q4 FY24: At a Glance Revenues from Highlights of Q4 FY24 R&D Operations ❑ Total revenues grew 10% YoY, led by growth across all key markets. Rs. 55,338 mn Rs. 3,516 mn ❑ India branded formulations business grew faster than the market driven 10% YoY 6.4% of revenues by portfolio of key pillar brands
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 66.2% 67.4% 70.9% 63.4% 68.1% 39,223 1,33,192 55,338 195474 50,106 172374 33,146 45,052 30,367 1,09,273 Q4FY23 Q3FY24 Q4FY24 FY23 FY24 Q4FY23 Q3FY24 Q4FY24 FY23 FY24 Total R&D (Rs. mn) and % to Revenues EBIT
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 38737 11,823 2,137 2,126 9,579 2,040 8,628 8,979 7,896 25645 Q4FY23 Q3FY24 Q4FY24 FY23 FY24 Q4FY23 Q3 FY24 Q4 FY24 FY23 FY24 Net Debt/ EBITDA Net Working Capital* (Rs. mn) 63,906 65,354 Q4FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4F
Slide 7: India Formulations business
India Formulations business Branded business delivered healthy growth Highlights for the quarter India Formulations Sales Q4 FY24 Revenue India Formulations Sales (Rs. mn) Contribution (Rs. mn) ▪ Branded business grew faster than the market with 8% YoY growth. 14,273 13,806 12,896 53,690 49,111 Port
Slide 8: Consumer Wellness
Consumer Wellness Demand recovery across portfolio further fueled by summer oriented brands Highlights for the quarter Consumer Wellness Sales Q4 FY24 Revenue Consumer Wellness Sales (Rs. mn) Contribution (Rs. mn) ▪ FMCG sector witnessed gradual recovery in demand 7,075 7,755 23,017 with an uptick i
Slide 9: US Formulations business
US Formulations business Crossed US$ 1 bn revenue milestone (FY24) Highlights for the quarter US Formulations Sales Q4 FY24 Revenue US Formulations Sales (Rs. mn) Contribution (Rs. mn) ▪ Base business grew sequentially every quarter 25,235 86,851 through the year driven by volume expansion and new 2
Slide 10: Emerging Markets & Europe Formulations business
Emerging Markets & Europe Formulations business All key markets continued to display strong momentum Highlights for the quarter EM & EU Formulations Sales Q4 FY24 Revenue EM & EU Formulations (Rs. mn) Contribution Sales (Rs. mn) ▪ Demand scenario remained strong across key 4,937 4,960 19,294 emergin
Slide 11: Updates on Innovation (1/2)
Updates on Innovation (1/2) NCE: Saroglitazar Magnesium • Completed recruitment of patients for Phase II(b)/ III clinical trials for PBC indication for the US market. The trials will study the effects of a molecule relative to placebo over 52 weeks across 100 sites. • Phase II(b) clinical trials for
Slide 12: Updates on Innovation (2/2)
Updates on Innovation (2/2) NCE: Desidustat • National Medical Products Administration of China accepted an NDA of the molecule made by China Medical System Holdings Limited (CMS). Phase III clinical trials in China demonstrated positive results. • In the year 2020, granted an exclusive license for
Slide 13: Zydus at a Glance
Zydus at a Glance ~$2.35 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Among 1st Revenues from India Approved product for 40% In ~60% of product Geography (Formulations Top 3 families marketed in US4
Slide 14: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q4 Q4 YoY Q3 QoQ YoY Rs. mn FY24 FY23 FY24 FY23 gr. % FY24 gr. % gr. % Total Income from Ops. 55,338 50,106 10.4% 45,052 22.8% 1,95,474 1,72,374 13.4% Gross Contribution (GC) 39,223 33,146 18.3% 30,367 29.2% 1,33,192 1,09,273 21.9% Gross Margin % 70.9% 6
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q4 Q4 YoY YoY Rs. mn FY24 FY23 FY24 FY23 gr. % gr. % A. On operating transactions (above EBITDA line) -57 590 -109.7% -864 -3,049 71.7% a. Included in COGS -4 5 -190% -54 -205 73.9% b. Part of other operating expenses (shown separately) -53 585 -810 -2,844 B. On
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C